Developer docs
API playgroundTry for free, no card

Search company profiles

TheracosBio

Full company profile

uuid000du5c

Namestring
TheracosBio
Legal namestring
TheracosBio, LLC
Websiteurl
theracosbio.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

TheracosBio is a privately held, single-product biopharmaceutical company headquartered in Framingham, Massachusetts, that develops and commercializes Brenzavvy (bexagliflozin), an oral SGLT2 inhibitor approved by the FDA in January 2023 for glycemic control in adults with type 2 diabetes. Brenzavvy works by inhibiting glucose reabsorption in the kidneys, promoting urinary glucose excretion, and is positioned as a once-daily, lowest-priced SGLT2 inhibitor in the US market following August 2024 IRA negotiated-price disclosures.

The company's business model is built on a PBM-free distribution strategy that bypasses traditional pharmacy benefit managers to deliver transparent pricing at approximately $47.75-$50 per month. Revenue is generated through pharmaceutical product sales across multiple channels, including Mark Cuban Cost Plus Drug Company, DiRx's national online pharmacy, the Independent Pharmacy Cooperative (IPC) serving 7,000+ pharmacies, PBA Health, Publix Pharmacy, and Wellgistics Health's 6,500+ pharmacy network. In August 2023, the company secured royalty financing from HealthCare Royalty (HCRx) to support the consolidated group of companies.

TheracosBio is operated by a lean executive team of approximately eight members covering regulatory affairs, clinical operations, CMC, quality assurance, supply chain, and finance, reflecting a virtual-commercialization model. The company has begun international expansion through a partnership with BAMCO Africa to serve Sub-Saharan Africa and has extended into the B2B marketplace via Cost Plus Drugs Marketplace for healthcare businesses. Revenue figures are not publicly disclosed.

Short descriptiontext

TheracosBio is a privately held biopharmaceutical company that develops and commercializes Brenzavvy (bexagliflozin), an FDA-approved oral SGLT2 inhibitor for adults with type 2 diabetes, distributed through PBM-free pharmacy channels at transparent pricing of $47.75-$50 per month.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFramingham, United States
HQ citystring
Framingham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
diabetes medication, SGLT2 inhibitor, pharmaceutical manufacturing, type 2 diabetes treatment, affordable pharmaceuticals
Industry1 code
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Type 2 Diabetes Pharmaceuticals
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue generated from the sale of Brenzavvy (bexagliflozin) through direct pharmacy distribution and pharmacy partners. The company offers transparent pricing at approximately $47.75-$50/month, bypassing PBMs to provide cost savings versus typical insurance copayments.

theracosbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Others
Pricing details2 tiers
1Standard monthly supply through pharmacy partners
ModelUnit PricingBilling cadenceMonthly
Notes

$50 per month or less through independent and online pharmacies; $47.75/month through DiRx online pharmacy; prices remain below typical insurance copayments due to PBM-free model

theracosbio.com
2Healthcare business marketplace pricing
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Available to healthcare businesses via Cost Plus Drugs Marketplace for B2B purchases

theracosbio.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Brenzavvy (bexagliflozin)
Description

FDA-approved oral SGLT2 inhibitor medication for adults with type 2 diabetes, approved by the U.S. Food and Drug Administration in 2023.

theracosbio.com
Core offering1 text field

TheracosBio develops, manufactures, and distributes Brenzavvy (bexagliflozin), an FDA-approved once-daily oral SGLT2 inhibitor for adults with type 2 diabetes. The company markets the drug at approximately $47.75–$50 per month through PBM-free pharmacy channels, partnering with online pharmacies, independent pharmacy cooperatives, retail chains, and emerging-market distributors to deliver affordable access.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Available at $50/month or less through pharmacy partners, below typical insurance copayments
+3 more records
Product overview1 text field

TheracosBio is a single-product pharmaceutical company focused on providing affordable medications for prevalent diseases. The company's sole product is Brenzavvy (bexagliflozin), an FDA-approved SGLT2 inhibitor for type 2 diabetes approved in January 2023. The product is distributed through multiple channels including Mark Cuban Cost Plus Drug Company, independent pharmacies via PBA Health and IPC, DiRx online pharmacy, and Wellgistics Health, bypassing traditional PBMs to offer affordable pricing at approximately $47-50 per month.

Product and service1 record
1Brenzavvy (bexagliflozin)
CategoryType 2 diabetes prescription drug
Description

FDA-approved once-daily oral SGLT2 inhibitor for adults with type 2 diabetes that reduces blood sugar and improves glycemic control as an adjunct to diet and exercise, marketed at transparent monthly pricing of $47.75-$50 through PBM-free pharmacy channels for individual patients.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-26
Description

Collaboration to provide affordably priced FDA-approved diabetes medication (BRENZAVVY) through Publix's retail pharmacy locations, expanding patient access to affordable treatments.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-10-17
Description

Partnership to bring affordably priced BRENZAVVY diabetes medication to Sub-Saharan Africa, expanding access to affordable diabetes care in emerging markets.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-10-03
Description

Strategic collaboration to expand access to Brenzavvy (bexagliflozin) through Wellgistics Health's 'maker-to-taker' platform, bypassing pharmacy benefit managers (PBMs) to reduce costs below typical insurance copayments. Partnership covers 6,500+ independent and chain pharmacies nationwide with rollout scheduled for Q4 2025.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-10-03
Description

Partnership to provide affordably priced FDA-approved BRENZAVVY to thousands of independent community pharmacies through PBA Health's distribution network.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-12-20
Description

BRENZAVVY distributed through IPC member pharmacies. IPC is the nation's largest group purchasing organization owned by independent pharmacy, serving more than 7,000 pharmacies. IPC was the first pharmaceutical wholesaler to carry and distribute BRENZAVVY in the US.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-12-18
Description

BRENZAVVY made available through DiRx's national online pharmacy at $47.75/month, eliminating hassles associated with insurance benefit design and providing direct-to-consumer access.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-08-17
Description

SmithRx offers BRENZAVVY to members with type 2 diabetes through its partnership with Mark Cuban Cost Plus Drug Company, providing PBM-free access to affordable diabetes medication.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-07-13
Description

Initial partnership launched commercial availability of BRENZAVVY at affordable prices. Extended in February 2024 to include healthcare business marketplace access. Cost Plus Drugs provides transparent pricing platform bypassing PBMs.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Lexicon is a small US biopharma that commercialized an SGLT1/2 inhibitor (Zynquista / sotagliflozin) in diabetes. Comparable to TheracosBio as a smaller, diabetes-focused branded pharma with a single SGLT asset navigating competition against larger incumbents.

TypeEmerging player
Description

vTv Therapeutics is a small clinical-stage diabetes-focused biopharma with a single lead asset (cadisegliptin). Comparable to TheracosBio as a small, diabetes-pure-play private or thinly-resourced pharma targeting the same type 2 diabetes market.

TypeEmerging player
Description

Esperion is a small public cardiometabolic biopharma focused on LDL-cholesterol therapies, competing in the same broad cardiometabolic prescriber channel that drives diabetes drugs. Comparable as a small specialized US commercial-stage cardiometabolic company.

TypeEmerging player
Description

Madrigal is a small US public biopharma with a single cardiometabolic asset (Rezdiffra for MASH). It is comparable to TheracosBio as a focused, single-product cardiometabolic company competing against Big Pharma in a high-prevalence disease category.

TypeBroad incumbent
Description

Merck markets Steglatro, an SGLT2 inhibitor for type 2 diabetes. It competes in the same drug class as Brenzavvy and is typically co-administered with sitagliptin. Merck is relevant as another large-pharma incumbent competing for the same SGLT2 share-of-voice.

6McKesson Corporation
TypeOthers
Description

McKesson is one of the largest pharmaceutical wholesalers in the US and a structural channel counterpart to TheracosBio's IPC, PBA Health, and Wellgistics distribution partners. Relevant as the dominant wholesale distributor model against which TheracosBio's PBM-free/wholesaler-light approach is contrasted.

TypeOthers
Description

Cost Plus Drugs is TheracosBio's anchor distribution partner and a direct-to-consumer pharmacy that bypasses PBMs. While not a competitor, it is a close ecosystem peer in the PBM-free, affordable-medicine mission and business model that defines TheracosBio's go-to-market.

TypeBroad incumbent
Description

AstraZeneca markets Farxiga, the leading SGLT2 inhibitor for type 2 diabetes. TheracosBio directly competes with bexagliflozin in the same drug class, with Farxiga setting the efficacy and pricing benchmark against which Brenzavvy is positioned as a non-inferior, lower-cost alternative.

TypeBroad incumbent
Description

Eli Lilly and Boehringer Ingelheim co-market Jardiance, the highest-prescribed SGLT2 inhibitor with established cardiovascular outcomes data. Like Farxiga, Jardiance defines the efficacy comparison against which Brenzavvy demonstrates non-inferiority, and is the primary competitive incumbent in the type 2 diabetes space TheracosBio targets.

TypeBroad incumbent
Description

Janssen markets Invokana, the first-approved SGLT2 inhibitor and a direct class competitor to bexagliflozin. Although canagliflozin share has eroded, Janssen's established commercial infrastructure and PBM contracts make it a structural competitor to TheracosBio's PBM-free positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TheracosBio

Type 2 Diabetes Pharmaceuticalstheracosbio.com

TheracosBio is a privately held biopharmaceutical company that develops and commercializes Brenzavvy (bexagliflozin), an FDA-approved oral SGLT2 inhibitor for adults with type 2 diabetes, distributed through PBM-free pharmacy channels at transparent pricing of $47.75-$50 per month.

What TheracosBio does

TheracosBio is a privately held, single-product biopharmaceutical company headquartered in Framingham, Massachusetts, that develops and commercializes Brenzavvy (bexagliflozin), an oral SGLT2 inhibitor approved by the FDA in January 2023 for glycemic control in adults with type 2 diabetes. Brenzavvy works by inhibiting glucose reabsorption in the kidneys, promoting urinary glucose excretion, and is positioned as a once-daily, lowest-priced SGLT2 inhibitor in the US market following August 2024 IRA negotiated-price disclosures.

The company's business model is built on a PBM-free distribution strategy that bypasses traditional pharmacy benefit managers to deliver transparent pricing at approximately $47.75-$50 per month. Revenue is generated through pharmaceutical product sales across multiple channels, including Mark Cuban Cost Plus Drug Company, DiRx's national online pharmacy, the Independent Pharmacy Cooperative (IPC) serving 7,000+ pharmacies, PBA Health, Publix Pharmacy, and Wellgistics Health's 6,500+ pharmacy network. In August 2023, the company secured royalty financing from HealthCare Royalty (HCRx) to support the consolidated group of companies.

TheracosBio is operated by a lean executive team of approximately eight members covering regulatory affairs, clinical operations, CMC, quality assurance, supply chain, and finance, reflecting a virtual-commercialization model. The company has begun international expansion through a partnership with BAMCO Africa to serve Sub-Saharan Africa and has extended into the B2B marketplace via Cost Plus Drugs Marketplace for healthcare businesses. Revenue figures are not publicly disclosed.

TheracosBio firmographics

Firmographics
Name
TheracosBio
Legal name
TheracosBio, LLC
Website
https://theracosbio.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Short description
TheracosBio is a privately held biopharmaceutical company that develops and commercializes Brenzavvy (bexagliflozin), an FDA-approved oral SGLT2 inhibitor for adults with type 2 diabetes, distributed through PBM-free pharmacy channels at transparent pricing of $47.75-$50 per month.
Ownership category
akta.pro rank

TheracosBio industry classification

Industry
Product category
Type 2 Diabetes Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Diabetes medication
  • SGLT2 inhibitor
  • Pharmaceutical manufacturing
  • Type 2 diabetes treatment
  • Affordable pharmaceuticals

Where TheracosBio is headquartered

Location

Headquarters

HQ city
Framingham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

TheracosBio business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Sales: Revenue generated from the sale of Brenzavvy (bexagliflozin) through direct pharmacy distribution and pharmacy partners. The company offers transparent pricing at approximately $47.75-$50/month, bypassing PBMs to provide cost savings versus typical insurance copayments.

Pricing tiers

ModelBillingPrice
Unit PricingMonthlyStandard monthly supply through pharmacy partners
Transaction based/ take ratePay-as-you-goHealthcare business marketplace pricing

Go-to-market motion3 records

Distribution channels7 records

Marketing channels4 records

TheracosBio product offering

Product offering

Core offering

TheracosBio develops, manufactures, and distributes Brenzavvy (bexagliflozin), an FDA-approved once-daily oral SGLT2 inhibitor for adults with type 2 diabetes. The company markets the drug at approximately $47.75–$50 per month through PBM-free pharmacy channels, partnering with online pharmacies, independent pharmacy cooperatives, retail chains, and emerging-market distributors to deliver affordable access.

Product overview

TheracosBio is a single-product pharmaceutical company focused on providing affordable medications for prevalent diseases. The company's sole product is Brenzavvy (bexagliflozin), an FDA-approved SGLT2 inhibitor for type 2 diabetes approved in January 2023. The product is distributed through multiple channels including Mark Cuban Cost Plus Drug Company, independent pharmacies via PBA Health and IPC, DiRx online pharmacy, and Wellgistics Health, bypassing traditional PBMs to offer affordable pricing at approximately $47-50 per month.

Differentiator

Problem solved

Functional benefit

Brands

  • Brenzavvy (bexagliflozin): FDA-approved oral SGLT2 inhibitor medication for adults with type 2 diabetes, approved by the U.S. Food and Drug Administration in 2023.

Products and services

  • Brenzavvy (bexagliflozin) FDA-approved once-daily oral SGLT2 inhibitor for adults with type 2 diabetes that reduces blood sugar and improves glycemic control as an adjunct to diet and exercise, marketed at transparent monthly pricing of $47.75-$50 through PBM-free pharmacy channels for individual patients.

Quantifiable outcome

  • Available at $50/month or less through pharmacy partners, below typical insurance copayments
  • +3 more outcomes

Companies that use TheracosBio

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles2 records

TheracosBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

TheracosBio partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and major.

  • Publix PharmacycoreChannel Partner/ Reseller/ Distributor · 26 June 2025Collaboration to provide affordably priced FDA-approved diabetes medication (BRENZAVVY) through Publix's retail pharmacy locations, expanding patient access to affordable treatments.
  • BAMCO AfricacoreChannel Partner/ Reseller/ Distributor · 17 October 2024Partnership to bring affordably priced BRENZAVVY diabetes medication to Sub-Saharan Africa, expanding access to affordable diabetes care in emerging markets.
  • Wellgistics HealthcoreChannel Partner/ Reseller/ Distributor · 3 October 2024Strategic collaboration to expand access to Brenzavvy (bexagliflozin) through Wellgistics Health's 'maker-to-taker' platform, bypassing pharmacy benefit managers (PBMs) to reduce costs below typical insurance copayments. Partnership covers 6,500+ independent and chain pharmacies nationwide with rollout scheduled for Q4 2025.
  • PBA HealthcoreChannel Partner/ Reseller/ Distributor · 3 October 2024Partnership to provide affordably priced FDA-approved BRENZAVVY to thousands of independent community pharmacies through PBA Health's distribution network.
  • Independent Pharmacy Cooperative (IPC)coreChannel Partner/ Reseller/ Distributor · 20 December 2023BRENZAVVY distributed through IPC member pharmacies. IPC is the nation's largest group purchasing organization owned by independent pharmacy, serving more than 7,000 pharmacies. IPC was the first pharmaceutical wholesaler to carry and distribute BRENZAVVY in the US.
  • DiRxmajorChannel Partner/ Reseller/ Distributor · 18 December 2023BRENZAVVY made available through DiRx's national online pharmacy at $47.75/month, eliminating hassles associated with insurance benefit design and providing direct-to-consumer access.
  • SmithRxmajorChannel Partner/ Reseller/ Distributor · 17 August 2023SmithRx offers BRENZAVVY to members with type 2 diabetes through its partnership with Mark Cuban Cost Plus Drug Company, providing PBM-free access to affordable diabetes medication.
  • Mark Cuban Cost Plus Drug CompanycoreChannel Partner/ Reseller/ Distributor · 13 July 2023Initial partnership launched commercial availability of BRENZAVVY at affordable prices. Extended in February 2024 to include healthcare business marketplace access. Cost Plus Drugs provides transparent pricing platform bypassing PBMs.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

TheracosBio competitors and assessment

Company assessment

Emerging players

  • Lexicon Pharmaceuticals: Lexicon is a small US biopharma that commercialized an SGLT1/2 inhibitor (Zynquista / sotagliflozin) in diabetes. Comparable to TheracosBio as a smaller, diabetes-focused branded pharma with a single SGLT asset navigating competition against larger incumbents.
  • vTv Therapeutics: vTv Therapeutics is a small clinical-stage diabetes-focused biopharma with a single lead asset (cadisegliptin). Comparable to TheracosBio as a small, diabetes-pure-play private or thinly-resourced pharma targeting the same type 2 diabetes market.
  • Esperion Therapeutics: Esperion is a small public cardiometabolic biopharma focused on LDL-cholesterol therapies, competing in the same broad cardiometabolic prescriber channel that drives diabetes drugs. Comparable as a small specialized US commercial-stage cardiometabolic company.
  • Madrigal Pharmaceuticals: Madrigal is a small US public biopharma with a single cardiometabolic asset (Rezdiffra for MASH). It is comparable to TheracosBio as a focused, single-product cardiometabolic company competing against Big Pharma in a high-prevalence disease category.

Broad incumbents

  • Merck (Steglatro / ertugliflozin): Merck markets Steglatro, an SGLT2 inhibitor for type 2 diabetes. It competes in the same drug class as Brenzavvy and is typically co-administered with sitagliptin. Merck is relevant as another large-pharma incumbent competing for the same SGLT2 share-of-voice.
  • AstraZeneca (Farxiga / dapagliflozin): AstraZeneca markets Farxiga, the leading SGLT2 inhibitor for type 2 diabetes. TheracosBio directly competes with bexagliflozin in the same drug class, with Farxiga setting the efficacy and pricing benchmark against which Brenzavvy is positioned as a non-inferior, lower-cost alternative.
  • Eli Lilly / Boehringer Ingelheim (Jardiance / empagliflozin): Eli Lilly and Boehringer Ingelheim co-market Jardiance, the highest-prescribed SGLT2 inhibitor with established cardiovascular outcomes data. Like Farxiga, Jardiance defines the efficacy comparison against which Brenzavvy demonstrates non-inferiority, and is the primary competitive incumbent in the type 2 diabetes space TheracosBio targets.
  • Johnson & Johnson / Janssen (Invokana / canagliflozin): Janssen markets Invokana, the first-approved SGLT2 inhibitor and a direct class competitor to bexagliflozin. Although canagliflozin share has eroded, Janssen's established commercial infrastructure and PBM contracts make it a structural competitor to TheracosBio's PBM-free positioning.

Others

  • McKesson Corporation: McKesson is one of the largest pharmaceutical wholesalers in the US and a structural channel counterpart to TheracosBio's IPC, PBA Health, and Wellgistics distribution partners. Relevant as the dominant wholesale distributor model against which TheracosBio's PBM-free/wholesaler-light approach is contrasted.
  • Mark Cuban Cost Plus Drug Company: Cost Plus Drugs is TheracosBio's anchor distribution partner and a direct-to-consumer pharmacy that bypasses PBMs. While not a competitor, it is a close ecosystem peer in the PBM-free, affordable-medicine mission and business model that defines TheracosBio's go-to-market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

TheracosBio social profiles

Digital presence

TheracosBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TheracosBio leadership team

Management profile

Number of profiles

Profiles8 records

TheracosBio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TheracosBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TheracosBio

What does TheracosBio do?

TheracosBio develops, manufactures, and distributes Brenzavvy (bexagliflozin), an FDA-approved once-daily oral SGLT2 inhibitor for adults with type 2 diabetes. The company markets the drug at approximately $47.75–$50 per month through PBM-free pharmacy channels, partnering with online pharmacies, independent pharmacy cooperatives, retail chains, and emerging-market distributors to deliver affordable access.

Is TheracosBio a public or private company?

TheracosBio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was TheracosBio founded?

TheracosBio was founded in 2000. It employs 11 to 50 people.

Where is TheracosBio based?

TheracosBio is headquartered in Framingham, United States, in the North America region.

How does TheracosBio make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are TheracosBio's main competitors?

Emerging players on record are Lexicon Pharmaceuticals, vTv Therapeutics, Esperion Therapeutics and Madrigal Pharmaceuticals. Broad incumbents are Merck (Steglatro / ertugliflozin), AstraZeneca (Farxiga / dapagliflozin), Eli Lilly / Boehringer Ingelheim (Jardiance / empagliflozin) and Johnson & Johnson / Janssen (Invokana / canagliflozin). Others are McKesson Corporation and Mark Cuban Cost Plus Drug Company.

Does TheracosBio have an API?

No public API is recorded for TheracosBio.

What industry is TheracosBio in?

TheracosBio's product category is Type 2 Diabetes Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireOneroRx Launches Lower-Cost Diabetes Medication BrenzavvyOneroRx announced the immediate availability of Brenzavvy, a lower-cost SGLT2 inhibitor for type 2 diabetes, developed by TheracosBio. The drug is available at select pharmacies, including Medicap, Sinks, and Lee's Summit, with a limited-time $38 discount on a three-month supply.Gainesville SunWellgistics Health (NASDAQ:WGRX) and TheracosBio Partner to Expand Nationwide, PBM-Free Access to Brenzavvy(R), an FDA-Approved Diabetes Therapy, Through 6,500+ PharmaciesWellgistics Health (NASDAQ:WGRX) announced a strategic collaboration with TheracosBio to expand access to Brenzavvy (bexagliflozin), an FDA-approved SGLT-2 inhibitor for type 2 diabetes, through a network of 6,500+ independent and chain pharmacies nationwide. The partnership utilizes Wellgistics Health's 'maker-to-taker' platform, which bypasses pharmacy benefit managers (PBMs) to reduce costs below typical insurance copayments. The rollout is scheduled to begin in Q4 2025, positioning WGRX for near-term revenue impact.Stock TitanWellgistics Partners with TheracosBio to Expand Brenzavvy Access to 6.5K PharmaciesWellgistics Health and TheracosBio announced a partnership to expand access to Brenzavvy, an SGLT-2 inhibitor for type 2 diabetes, through 6,500+ pharmacies. The collaboration aims to lower costs below typical insurance copays and will integrate into Wellgistics' platform in Q4 2025.PR NewswireSGLT2 Inhibitors Market to Expand by 2034 as Companies Leverage Emerging Opportunities in Indications Such as Heart Failure, MASH, Obesity, PCOS, and Others | DelveInsightDelveInsight's market report projects significant growth for the SGLT2 inhibitors market through 2034, driven by rising prevalence of type 2 diabetes, chronic kidney disease, and expanding clinical indications including heart failure, obesity, and metabolic dysfunction-associated steatohepatitis. Emerging dual SGLT1/2 inhibitors in development include YG1699 (Youngene Therapeutics) and JP-2266 (Jeil Pharmaceuticals), both in Phase II trials, alongside approved therapies such as BRENZAVVY (TheracosBio) and JARDIANCE (Eli Lilly/Boehringer Ingelheim). Regulatory milestones and clinical data support market expansion, including INPEFA's 2025 trial showing a 23% reduction in cardiovascular events and Mitsubishi Tanabe Pharma's launch of CANALIA, the first once-daily oral DPP-4/SGLT2 inhibitor combination in Japan.Drug Store NewsTheracosBio to offer Brenzavvy through Mark Cuban Cost Plus Drug CompanyTheracosBio announced Brenzavvy (bexagliflozin) is now available by prescription through Mark Cuban Cost Plus Drug Company. A 30-day supply costs $47.85 plus shipping, with no insurance required. The drug is indicated for Type 2 diabetes and is not recommended for Type 1 diabetes.PharmiWeb.comTheracosBio Extends Partnership with Mark Cuban Cost Plus Drug CompanyTheracosBio extended its partnership with Mark Cuban Cost Plus Drug Company, making BRENZAVVY (bexagliflozin) available to healthcare businesses via the Cost Plus Drugs Marketplace. The SGLT2 inhibitor is priced at $47.85 per 30-tablet bottle, 90% below other class drugs, and is indicated for type 2 diabetes.FiercePharmaTheracosBio teams with Mark Cuban's Cost Plus to launch Brenzavvy at bargain priceTheracosBio launched Brenzavvy, an SGLT2 diabetes drug, on July 13 via Cost Plus Drug Company at $47.85 for a 30-day supply, undercutting competitors by roughly 1,000%. The company cites the low price as enabling patient access and savings.PR NewswirePIRAMAL PHARMA SOLUTIONS UNTERSTÜTZT THERACOSBIO MIT INTEGRIERTEM ARZNEIMITTEL-/ARZNEIMITTELPRODUKTPROGRAMM FÜR BEXAGLIFLOZINPiramal Pharma Solutions successfully completed the integrated development and manufacturing of Brenzavvy™ (Bexagliflozin), an FDA-approved oral SGLT2 inhibitor for Type 2 diabetes, supporting client TheracosBio in bringing the drug to market. The manufacturing program spanned multiple Piramal sites across India and the UK, producing regulatory starting materials, active pharmaceutical ingredients, and the finished tablet dosage form. The FDA approval, based on clinical data from over 5,000 participants across 23 trials, represents a significant milestone for TheracosBio and highlights the value of Piramal's end-to-end CDMO services.PR NewswirePIRAMAL PHARMA SOLUTIONS SOUTIENT THERACOSBIO AVEC UN PROGRAMME INTÉGRÉ DE SUBSTANCE MÉDICAMENTEUSE/PRODUIT MÉDICAMENTEUX POUR LA BEXAGLIFLOZINEPiramal Pharma Solutions successfully completed the integrated development and manufacturing of drug substance and drug product for Brenzavvy™ (bexagliflozine), TheracosBio's FDA-approved oral SGLT2 inhibitor for type 2 diabetes. The FDA approved Brenzavvy in January 2023 based on a clinical program spanning 23 trials with over 5,000 participants. The manufacturing program involved multiple Piramal sites across India and the United Kingdom, spanning several years of development.PR NewswirePIRAMAL PHARMA SOLUTIONS SUPPORTS THERACOSBIO WITH INTEGRATED DRUG SUBSTANCEPiramal Pharma Solutions completed integrated drug development and manufacturing for Brenzavvy (bexagliflozin), an FDA-approved SGLT2 inhibitor for type 2 diabetes. The program involved Piramal sites in India and Europe, including starting materials, API, and tablet formulation. The FDA approval was based on 23 clinical trials with over 5,000 participants.